During an equity round, questions about scale, product control or delivery remain open. Choose the record, test, fix or honest limit each answer needs, rather than a rebuild by default.
Our network includes CTOs, engineering leaders,
and technical advisers with experience at and around companies such as:
Investor questions remain open
Fundraising technical readiness starts with each actual question: what is supported, what remains unknown and which action is worth the runway it consumes?
Onboarding that needs the founder
In an equity round, your investor may ask whether onboarding works without the founder.
Components and data you control
Your investor may ask which components and data you control.
A next milestone in question
Your investor may ask whether the team can deliver the next milestone.
A demo answers a narrower question
A prepared-account demo and a feature roadmap have narrower evidence boundaries.
What needs proving next?
Choose the proportionate action for each question: locate a record, test an unknown, fix a gap or state a limit.
01
What records already answer
Can existing records answer the question, or does the claim need a test, fix or narrower scope?
02
Control and rights
What do you control in the product, and which code or data rights need separate legal review?
03
Your own AI contribution
What evidence separates your AI contribution from supplier capabilities and manual work?
04
Milestone feasibility
Is the next milestone feasible with the people, dependencies and budget actually available?
05
Work that still needs people
Which onboarding or support work still needs people, and what changes at the next volume?
Match work to evidence
An existing record, an unresolved contradiction and a confirmed delivery gap need different responses.
01
Prepare with your existing lead
If dated records answer the question and an accountable lead or vendor can explain their limits, keep preparation internal. The founder owns the response and agrees any routine follow-up with the current technical owner.
02
Review the founder’s evidence priorities
If a roadmap conflicts with operating records, use Technical due diligence & investor readiness to review founder-side priorities. The founder agrees which technical answer needs attention.
If founder-only setup blocks the promised customer milestone, agree Fractional CTO services to lead the bounded change. Define technical authority and capacity; the founder accepts the milestone's remaining limits.
If the wider claim cannot yet be supported, the founder can state the narrower capability and propose the next evidence milestone. Name its owner, dependencies and resource assumptions; the investor's reviewer judges the response.
A traceable technical response
Agree the technical questions of one equity funding stage and whether the scope includes verification, experiments or remediation leadership. Proposed outputs may include:
01Evidence index
Linking each technical answer to dated artifacts.
02Prioritized gap register
With consequences, owners and current status.
03Milestone plan
With resource, cost and dependency assumptions visible.
04Response record
Separating evidence, residual risk and the CTO's own judgment.
Your team or chosen vendor gathers records, runs agreed checks and implements changes. The curator conversation establishes fit, not a diligence conclusion. A submitted pack is not an accepted answer or an investment decision.
Related cases
Success stories and business challenges from our CTOs’ own work before Grand Rounds.
Tell the curator which investor question remains unanswered, what evidence exists and what decision must be made before the next review. Use nonconfidential context; keep board papers, contracts and credentials out.
We work best with founders who believe in what they are building
Every founder brings a different challenge. What stays the same is how we approach it.
David CarrollFounder of EuryanDavid came to Grand Rounds with two open questions he wanted pressure-tested before taking them to investors: how Euryan should handle LLM and cloud strategy across different client environments, and whether the core product wedge, dynamic FMEA/8D automation, was the right foundation to build the rest of the roadmap on.
Susie WilliamsFounder of LinkEDtohomeSusie came to Grand Rounds with two questions she wanted pressure-tested before LinkEDtohome moved beyond its first school: how to scale the team and technology without building too far ahead of real demand, and what needed to be in place around AI liability, training and governance before broader adoption.
Alexander GorrieFounderAlex came to CTO Grand Rounds with several important technical decisions already being actively worked through. One question from the panel reframed the discussion: “How will you know that the result is actually good?” It sharpened the conversation around how those decisions should be sequenced and prioritised.
Tomas JankauskasFounder of Neural DEEPTomas came to Grand Rounds with a question he'd been wrestling with while bringing AI-driven innovation into Toyota: which ideas to pursue, and how much to build before anything was approved, in an organisation where every new idea needs to pass through many hands.
Dr. Lars ZimmermannFounder of Ahead Care GmbHLars came to Grand Rounds looking for an experienced second opinion on the hardware challenges facing MOIO, Ahead Care's wearable care technology. He wanted to explore practical options for the product's development and gain a fresh perspective from someone who had navigated similar challenges in medical wearables.
1 / 5
Products with a purpose
Technology that delivers a real outcome for people, not technology for its own sake.
Energy and enthusiasm
Founders and teams with the passion and drive to address a problem they have seen for themselves.
The story before the numbers
The first question is what you are trying to do and why: what you saw and why you started.
Listening more than talking
Nobody walks in to say “I know better.” We ask what drives a decision and what has not been considered, then work through the options together.
Understanding before fixing
First the people, the business and the why, and what has and has not worked, so the first problem found does not start constant firefighting.
Experience, not just knowledge
Modern and AI tools assist. Architecture, security, recovery and user experience still need people who have built and run real systems.
Select for technical scrutiny
Engineering foundations, technical strategy and founder investment preparation are represented in our CTO network. Choose for scrutiny of the specific claim and the work needed to support it.
Look for a CTO who can show:
Roadmap staffing challenged against committed capacity, not planned hires.
Tested scaling limits distinguished from founder-dependent operations.
Remediation narrowed to the evidence a specific investor question needs.
Own AI components and data separated from suppliers and manual work.
Use an open investor question to discuss the needed scrutiny and bounded change with the curator. Select for evidence and judgment rather than a funding total.
If a fund introduces you, agree the client, payer and permitted recipients separately; the introduction grants no automatic access to findings.
Neil began his career writing code for the nuclear industry and has since held CTO, Chief Architect, and Director roles at BT, Wipro, Fujitsu, Sopra Steria, and Capita - including a strategic Google (GCP) partnership at BT, the architecture of a country-wide health service in India at Wipro, and a five-year strategic roadmap for UK Government Home Affairs at Fujitsu.
Fractional CTO — technology strategy, delivery recovery and engineering leadership
Jerome MacGillivray has spent more than twenty-five years leading global technology teams and delivering digital platforms across regulated, customer-facing and operationally complex environments. His experience spans fintech, retail, travel, cybersecurity, robotics and AI, with roles covering CTO leadership, engineering scale-up, vendor management, platform delivery and technical recovery. He works with founders, boards and leadership teams to make technology decisions clearer, delivery more predictable, and engineering more closely aligned with business priorities.
Gloucester, UKPlatform recoveryProduct and engineering strategyVendor and technical due diligence
Reon began his career as an electronic engineer at TEGEMA, a high-tech engineering company in the Eindhoven Brainport region, designing electronics and electrical systems for machines and products in semiconductor, life science and automotive markets, including his first medical products.
Ryan is an electrical and electronic engineer who began his career as a semiconductor market analyst at IMS Research, later IHS, where over a decade he built one of the industry’s leading wireless-power research practices and led international analyst teams to around 64% year-on-year revenue growth. He has worked with Aircharge for eleven years, progressing from commercial development to CTO and Managing Director, and now serves on its board as a Non-Executive Director. There he helped lead the evolution of a wireless-charging hardware business into an international physical-digital platform spanning hardware, SaaS, IoT and data, deployed across 4,500+ venues in 45+ countries with major global hospitality, QSR and technology brands.
London Area, United KingdomFounders, CEOs & leadership teamsConnected hardware, IoT, SaaS/data & AI-enabled productsProduct launch to international scale
Carlos spent 14 years inside TransUnion, moving from software developer to DevOps engineer to Product Owner, learning exactly how large financial institutions think, what slows them down, and where the cracks are. Then he left to help founders build things faster than those institutions ever could.
CanadaAI agentsFintech & creditEarly-stage MVPsFull-stack architectureStartup to enterprise
Fractional CTO — Scientific Computing, AI & Data for Life Sciences
Arno is a mathematician who has spent more than 25 years building software that applies algorithms and machine learning to life science questions, long before “AI” became the word for it. He joined Definiens as a software developer in 1998 and spent over two decades there, progressing through Director of Platform Development, Chief Architect, VP Product Development and VP & Chief Architect to VP Product & Innovation at Definiens, The Tissue Phenomics Company. Along the way he took the company’s image analysis technology from an early prototype to its core product, was responsible for that product for many years, and later brought up and matured new products and technologies in digital and computational pathology. Since 2020 he has been CTO of Noselab, a Munich biotech company, where he built the entire digital side of the business, from software and IT to data, along with the team behind it, working hands-on throughout. He is a named inventor on multiple patents in image analysis, has co-authored publications on tissue phenomics and cancer research, and serves as a panel CTO with CTO Grand Rounds. He holds a Diplom in Mathematics from Ludwig-Maximilians-Universität München.
Munich Area, GermanyBiotech, pharma & digital pathologyFrom research to productEarly prototype to early scaling
Fractional CTO/CIO — Health & Care, Government, Commercial | ex-NHS, ex-InHealth
With a career spanning founding and co-founding technology businesses, consultancy, interim executive, and non-executive board roles across the NHS, government, charity, and commercial sectors, Andrew has spent close to four decades helping organisations use information and technology to drive meaningful change.
Brisbane, AustraliaUK & AustraliaDigital transformationHealth & care sectorBoard advisory (NED/Interim)
Applied AI Adviser — Oxford DPhil, ex-J.P. Morgan, UBS, Citi
Berkan has worked on AI in high-stakes settings since 2009, starting with an Oxford DPhil in AI and Medical Informatics, where he built clinical decision support systems that predicted patient outcomes and recommended treatment, published in leading medical and interdisciplinary journals. He has published on AI continuously since, most recently on the evaluation of retrieval-augmented LLMs in clinical use, and writes for industry on AI transformation and clinical AI.
Fractional CTO & Board Adviser — Applied AI, WealthTech and High-Performance Teams in Regulated Markets
Neil Taggart has spent his career leading technology and product functions across financial services, wealth management and, more recently, applied AI. His experience includes two CTO roles in regulated financial markets, nearly nine years leading technology for a global strategy-execution consultancy through its acquisition by a Fortune 1000 firm, and building the technology function for a Family Office wealth management business, alongside hands-on AI coaching and product work with Tribe AI and Anthropic.
London, UKApplied AI & enterprise adoptionWealthTech & family office technologyHigh-performance team coaching
Fractional CTO/CIO & Board Adviser — Enterprise Modernization, Security & Compliance and Large-Scale Operations in Regulated Industries
Amer Murad has spent 27+ years leading technology, product and operations functions across healthcare, human capital management, education, telecom and banking. His experience includes CTO and CIO roles spanning organizations from a 300-person SaaS communications platform to a 10,000-employee not-for-profit healthcare provider, 16 years at Ceridian leading product development, technology innovation and DevOps for global HCM and payroll platforms, and building a compliance and governance function from scratch for a 45-year-old software company through its growth by acquisition. He is TOGAF 9 certified in enterprise architecture.
Hamilton, Ontario, CanadaEnterprise technology & data modernizationSecurity, risk & compliance (SOC 2, GDPR, HIPAA)Large-scale program & operations leadership
Fractional CTO — Precision Biology, Drug Discovery & Translational Science in Regulated Industries
Elad Katz has spent over two decades working at the intersection of deep biological science and commercial reality, leading translational research and venture creation across oncology, kidney, liver, cardiac, bone and women's health. His experience spans founding and leading Navigate Precision Biology, where he built the NaviPlate organoid platform from academic concept through customer discovery to commercial validation, alongside senior scientific and R&D leadership roles at Sartorius Stedim BioOutsource, amsbio, and the Universities of Edinburgh, Manchester and Pennsylvania. He holds a PhD in Immunology from the University of Glasgow and a BSc in Chemistry and Physics from the Hebrew University of Jerusalem.
Greater Dundee Area, UKPrecision medicine & drug discoveryOrganoid biology, disease modelling & assay developmentCommercial translation for biotech & pharma
Gabriel began his career as a technical systems analyst and test engineer in the Israeli Air Force, reaching the rank of Major and taking part in several satellite launches, before leading system engineering and testing on large multidisciplinary programmes at Israel Aerospace Industries. He went on to senior system engineering and technical product roles at Orbotech and OSR Enterprises, then moved into regulated medical devices in Sydney as Technology Development Lead at Nanosonics and Principal Engineer for robotics and automation across Cochlear's global manufacturing operations.
Sydney, AustraliaScale-ups, pivots & health servicesMedical devices, AI, robotics, aerospaceSingle-owner projects to 400-person global teams
Fractional CTO & AI Engineer — AI for High-Compliance B2B SaaS
Márton began his career in research, completing a PhD in computer systems and networking at the Budapest University of Technology and Economics, with a research internship at Deutsche Telekom's T-Labs in Berlin, followed by four years as a postdoctoral research fellow at the Hungarian Academy of Sciences, where he published peer-reviewed research in neuroscience and distributed systems. He moved to Berlin to join KILT Protocol as Research Lead, Product Owner and Full Stack Developer, designing its self-sovereign digital identity protocol and token economics, authoring its white paper, and leading delivery from research through to mainnet, including a Deloitte-partnered KYC integration.
Rodion is a product strategist and the founder of Curiosity Office™, his practice for product vision and strategy. Over fifteen years he has shipped products and advised founders, banks and government offices. He comes in, sees what the team can no longer see, and leaves behind a product that looks like it was always meant to exist.
I've spent 12 years building partnerships between founders, technical teams, and the people
who fund them. Somewhere along the way I noticed the same pattern over and over:
brilliant fractional CTOs, and founders who had no idea they existed, let alone how
to reach them.
Grand Rounds is my answer to that gap. The name comes from medicine, when a case is hard,
doctors don't decide alone, they bring senior specialists around the table together.
I built the same thing for technology.
"People need people. Nothing else works."
I'm the one who listens to your problem, asks the questions you didn't think to ask
yourself, and explores which experience in the network is relevant to it.
Jane has been working across the industry since 2014, connecting
startups, retailers, B2B companies, manufacturers, and expert teams around meaningful
partnership opportunities.
Her experience includes building bridges between companies and ecosystems, ready-made
technology solutions, manufacturing-focused initiatives, and sustainability-driven
projects. Over the years, she has helped create practical collaboration models between
businesses, technology providers, and industry experts.
For Jane, partnership strategy is not just part of the work - it is the DNA of her
professional experience. Her focus is on identifying where teams, platforms, products,
and industries can strengthen each other and turning those connections into real
opportunities.
What founders say after their Grand Rounds session
It's like a hackathon for your real business problems. You bring your
challenges and bright minds work on them - with no obligation, no pressure. I walked away
with perspectives on investors, encryption solutions, and a connection that could directly
benefit my product. Honestly, why rely on one mind, when you can have many?
Saif AlamCEO at Keepsta
It was an incredibly welcoming space to connect with senior technical minds
I wouldn't normally have access to as a non-technical founder. A fantastic opportunity to get
real, honest answers to the challenges I was facing - and to walk away with meaningful
connections who continue to support me.
Audrey LeeFounder of Lumi
CTO Grand Rounds was the best event by far. This is where the founder world
and the tech world actually merge, with real introductions instead of leaving people to stay
siloed. I was deep in a conversation about cybersecurity and feedback loops - practical
advice I could act on immediately.
Hélène Le RouxCEO at Trippin'
What I valued most was the mix of CTO styles at the table - some all-in on
AI, others more measured. As a founder, you don't want someone else's answer, you want enough
perspectives to make your own call. I walked away with two strong contacts - people who hit
the mark on build support, strategic fit, and investor credibility. The relaxed format made
room for real technical conversation, not just quick decisions. Worth coming back for.
Hew WilliamsFounder of Zeorb
FAQ
Before commissioning the work
The work supports technical answers and risk priorities, not investor acceptance, valuation or funding. The founder and responsible fundraising adviser lead the raise; commercial, financial and legal advisers retain their scopes. Technical evidence cannot settle demand or business-model questions.
Clarify what decision the question informs and what evidence the reviewer expects. Favor work that can change the answer with the access and capacity available. A missing rights interpretation may need counsel, while an operator-dependent flow may need a bounded technical check.
Not by default. Choose the action the gap warrants: an existing record may suffice, an unknown may need a test, and a demonstrated defect may need a fix. If evidence remains incomplete, state the limit and a feasible next milestone. These are alternatives, not a mandatory record-to-test-to-fix sequence.
This page concerns an equity investor's technical review; grants and procurement checks have different requirements.
An investor's own conclusion needs a separate mandate; see Technical due diligence & investor readiness (linked below).
We use Google Analytics cookies to see how visitors use this site. They are set only if you accept, and you can change your mind with Cookie settings at the foot of every page.